Lithuanian medtech Sentante secures €6M in a Seed round led by Practica Capital

Kaunas-based pioneering medical device company Sentante has secured €6 million in a Seed funding round led by Practica Capital with the participation of the EIC fund. The funds will help with the clinical trials of the Sentante robotic system and further product launch.

  • Founded in 2017, Sentante is an innovative teleoperated robotic system developed by UAB Inovatyvi Medicina. It allows an entire endovascular intervention to be performed remotely, from a different room, so physicians and the entire medical team can work without being exposed to harmful X-ray radiation.
Sentante robotic system. Image: Sentante
  • This innovation bears profound significance, particularly in critical cases such as stroke and heart attacks, which involve over six million procedures annually, where each passing minute significantly impacts the chances of a good outcome.

“We are thrilled to partner with Sentante, a company that aligns perfectly with our philosophy of supporting transformative innovations. With its unique teleoperated endovascular intervention system, Sentante is set to redefine surgical practices globally, improving both patient outcomes and the well-being of medical professionals. This investment underscores our commitment to advancing healthcare technologies that have the potential to create a significant, positive impact worldwide,”

Tomas Andriuškevičius, partner at Practica Capital, comments.
  • Practica Capital is the lead investor in the company. It is an early-stage VC dedicated to backing Baltic founders. The firm manages four funds with more than €130 million in AUM. To date, the firm made over 60 investments, including great companies like Atrandi, Oxipit, Biomatter Designs, PVcase, and others.
  • The round also received support from the European Innovation Council fund. It is an EU-backed agnostic fund investing across all technologies and verticals, and all EU countries.

The company will use the proceeds from the financing for the planned clinical trial of the Sentante robotic system and preparation of commercial launch in targeted international markets.